2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 328

Implementation of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Documentation in Systemic Lupus Erythematosus (SLE) Patients at an Academic Medical Center
Abstract Number: 329

Use of Inter-Professional Collaboration to Improve Adherence to American College of Rheumatology Recommendations for Use of Disease Activity Measures
Abstract Number: 330

The IMPACT of a Referral Algorithm for Axial Spondyloarthritis: Four Month Follow-up in Patient Reported Outcomes
Abstract Number: 331

Development and Implementation of a Patient-Reported Outcomes Measurement Information System (MyRheum)
Abstract Number: 332

Components of Impaired Physical Function and Disability in a Non-Rheumatic Population. Normative Values of the Health Assessment Questionnaire Disability Index
Abstract Number: 333

Electronic Delivery of Patient-Reported Outcome Questionnaires on Tablet PCs at Clinic Visit: A Feasibility Study
Abstract Number: 334

Use of Handheld Device to Enhance Patient Reported Outcome Measure Data Collection in an Academic Rheumatology Practice
Abstract Number: 335

Cross-Cultural Validity of Functional Status Assessment Measures for Rheumatoid Arthritis
Abstract Number: 336

Physical Activity Monitors: New Tool to Assess Improvement in Myositis
Abstract Number: 337

Does a Best Practice Alert Improve RA Patient Referral to Preventative Cardiology?
Abstract Number: 338

Implementation of an Automated Phrase to Increase Awareness of Cardiovascular Risk in Rheumatoid Arthritis Patients in an Urban Fellows Rheumatology Clinic
Abstract Number: 339

Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic
Abstract Number: 340

No Improvement in Time to Biopsy and Therapy in Lupus Nephritis Patients over Two Decades
Abstract Number: 341

Setting Treatment Target for Joint Surgery in Lower Limbs in Patients with Long-Standing Rheumatoid Arthritis Based on Multicenter Prospective Cohort Study; Validation and Reliability of Objective Index of Activity Speed (Timed Up and Go test) for Measuring Physical Function
Abstract Number: 342

Optimizing the Dataset to Collect from Patients to Accurately Predict Their Status Prior to the Clinic Visit

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].